Accel Partners
+18.64%
3M Return
$38.970
-0.631 (-1.62%)At close
Ethos Technologies Inc. is a United States-based life insurance company. The Company offers whole life insurance and term life insurance. Its whole life insurance provides accidental death benefit and death benefit. Its term life insurance offers monthly payment of premiums that do not increase during the term. It is provided for age 65-85 years. Its term life insurance provides coverage for a term typically 10-30 years. The Company operates in every United States and the District of Columbia.
Ethos Technologies Inc. is a good buy right now due to its impressive recent performance and strong growth outlook. The current price is $36.96, and the company reported a 113.8% year-over-year revenue growth in Q2 2026, reaching $190 million, which significantly exceeded market expectations. Additionally, the gross margin stands at an impressive 97.06%, indicating strong profitability. However, a risk to consider is the recent downgrade by JPMorgan, which cites valuation concerns after a strong run, indicating a potential for price stabilization.

Ethos Technologies to Release Q3 2026 Financial Results

Ethos Signs Erin Andrews as Brand Ambassador

aTyr Pharma Presents Significant Advancements in Efzofitimod Research

Ethos Technologies Reports Strong Q2 Results, Shares Surge 24%

Ethos Technologies Reports Exceptional Q2 2026 Earnings Growth
Ethos Technologies Inc. is a United States-based life insurance company. The Company offers whole life insurance and term life insurance. Its whole life insurance provides accidental death benefit and death benefit. Its term life insurance offers monthly payment of premiums that do not increase during the term. It is provided for age 65-85 years. Its term life insurance provides coverage for a term typically 10-30 years. The Company operates in every United States and the District of Columbia. It operates in the Financials sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Ethos Technologies Inc. is a good buy right now due to its impressive recent performance and strong growth outlook. The current price is $36.96, and the company reported a 113.8% year-over-year revenue growth in Q2 2026, reaching $190 million, which significantly exceeded market expectations. Additionally, the gross margin stands at an impressive 97.06%, indicating strong profitability. However, a risk to consider is the recent downgrade by JPMorgan, which cites valuation concerns after a strong run, indicating a potential for price stabilization.
No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.